Alnylam Pharmaceuticals announced this week that it has struck an RNAi drug discovery and development alliance with Novartis Pharmaceuticals. The deal will bolster Alnylam's coffers with millions in upfront fees and equity investments, and calls for Novartis to take a 19.9 percent equity stake in the RNAi-based drugs developer.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Browse our free articlesYou can still register for access to our free content.